04023nam 22006615 450 991029833630332120200702125853.03-7091-1818-210.1007/978-3-7091-1818-4(CKB)3710000000281304(EBL)1966148(OCoLC)899003845(SSID)ssj0001385856(PQKBManifestationID)11883459(PQKBTitleCode)TC0001385856(PQKBWorkID)11340615(PQKB)10064177(MiAaPQ)EBC1966148(DE-He213)978-3-7091-1818-4(PPN)18308778X(EXLCZ)99371000000028130420141113d2014 u| 0engur|n|---|||||txtccrNovel Technologies for Vaccine Development /edited by Igor S Lukashevich, Haval Shirwan1st ed. 2014.Vienna :Springer Vienna :Imprint: Springer,2014.1 online resource (393 p.)Description based upon print version of record.3-7091-1817-4 Includes bibliographical references at the end of each chapters.Reverse Genetics Approaches for Rational Design of Inactivated and Live-Attenuated Influenza Vaccines -- Viral-Vectored Vaccines to Control Pathogenic Filoviruses -- Alphavirus Replicon Vectors for Prophylactic Applications and Cancer Intervention -- Current Status and Future of Polio Vaccines and Vaccination -- Current Status of Hantavirus Vaccines Development -- Experimental DNA-Launched Live Attenuated Vaccines against Infections Caused by Flavi- and Alphaviruses -- Sugar-Based Immune Adjuvants for Use in Recombinant, Viral, Vector, DNA and Other Styles of Vaccines -- Adenovirus-based Vectors for the Development of Prophylactic and Therapeutic Vaccines -- Radiovirotherapy for the Treatment of Cancer -- TRICOM Poxviral-Based Vaccines for the Treatment of Cancer -- The Use of Oncolytic Herpesvirus for the Treatment of Cancer -- SA-4-1BBL; A Novel form of the 4-1BB Costimulatory Ligand as an Adjuvant Platform for the Development of Subunit Cancer Vaccines.This book presents a detailed overview of the development of new viral vector-based vaccines before discussing two major applications: preventive vaccines for infectious diseases and therapeutic cancer vaccines. Viral vector-based vaccines hold a great potential for development into successful pharmaceutical products and several examples at the advanced pre-clinical or clinical stage are presented. Nevertheless, the most efforts were focused on novel and very innovative technologies for new generation of vector-based vaccines. Furthermore, specific topics such as delivery and adjuvant and protection strategies for cell-mediated-based vaccines are presented. Given its scope, the book is a “must read” for all those involved in vaccine development, both in academia and industrial vaccine development.VaccinesPharmaceutical technologyImmunologyVaccinehttps://scigraph.springernature.com/ontologies/product-market-codes/B16010Pharmaceutical Sciences/Technologyhttps://scigraph.springernature.com/ontologies/product-market-codes/B21010Immunologyhttps://scigraph.springernature.com/ontologies/product-market-codes/B14000Vaccines.Pharmaceutical technology.Immunology.Vaccine.Pharmaceutical Sciences/Technology.Immunology.610615.19615372616079Lukashevich Igor Sedthttp://id.loc.gov/vocabulary/relators/edtShirwan Havaledthttp://id.loc.gov/vocabulary/relators/edtBOOK9910298336303321Novel Technologies for Vaccine Development2498397UNINA